Summary of Puma Biotechnology FY Conference Call Company Overview - **Company**: Puma Biotechnology (NasdaqGS: PBYI) - **Key Product**: NERLYNX (neratinib), FDA approved for HER2-positive breast cancer - **Pipeline Drug**: Alisertib, an Aurora kinase inhibitor in clinical trials Key Points Product Pipeline - NERLYNX is approved for both extended adjuvant and metastatic HER2-positive breast cancer based on Phase III trials (ExteNET and NALA) [4][30] - Alisertib is in two Phase II trials: ALISCA-Breast for HER2-positive and HER2-negative metastatic breast cancer, and ALISCA-Lung for small cell lung cancer [4][30] Commercialization and Revenue - NERLYNX generated **$59.9 million** in Q4 2025, up from **$54.4 million** in Q4 2024 and **$51.9 million** in Q3 2025 [5][6] - Total bottles sold in Q4 2025: **3,298**, compared to **2,964** in Q4 2024 and **2,949** in Q3 2025 [6] - Expected revenue for full year 2026: **$214 million - $221 million**, with a net income of **$10 million - $13 million** [9] Market Potential - U.S. market for NERLYNX in the extended adjuvant setting: approximately **28,300** patients with early-stage HER2-positive breast cancer [8] - In the EU, about **37,000** patients with early-stage HER2-positive breast cancer, with **65%-70%** being HR-positive [8] Clinical Trials and Efficacy - Alisertib shows promise in various cancers, with a focus on HR-positive, HER2-negative breast cancer and small cell lung cancer [12][19] - In previous trials, alisertib demonstrated a **23%** objective response rate in HR-positive, HER2-negative breast cancer [14] - Ongoing studies aim to optimize dosing and evaluate biomarkers for better efficacy [18][24] Intellectual Property - NERLYNX patents extend to **2030**, with additional use patents until **2031** [25] - Alisertib's composition patent extends to **2029**, with further extensions for specific uses until **2034** [26] Financial Health - Cash and cash equivalents at the end of December: **$97.5 million** [29] - The company has maintained profitability since 2016, with a focus on staying net income positive [41][42] Future Milestones - Interim data from ALISCA-Breast1 and ALISCA-Lung1 trials expected in **2026** [27] - Full data from ALISCA-Breast1 anticipated in **Q4 2026** [28] Management and Governance - CEO: Alan Arak, with a diverse board covering commercial, clinical, finance, and regulatory aspects [28] Additional Insights - The FDA's preference for randomized studies over single-arm approvals may impact future drug approval strategies [36] - The company is exploring biomarker-directed approaches to enhance treatment efficacy [36][40] This summary encapsulates the key points discussed during the Puma Biotechnology FY Conference Call, highlighting the company's product pipeline, commercialization efforts, market potential, clinical trial outcomes, financial health, and future milestones.